It has becoming a familiar refrain around the world , and is certainly good news for the prostate cancer community! This week, another androgen receptor pathway inhibitor (ARPI) became reimbursed for men with hormone-sensitive metastatic prostate cancer (mHSPC) in Australia. Darolutamide is already available for men with non-metastatic castration-resistant prostate cancer, and is now also available for men with mHSPC in combination with androgen deprivation therapy and chemotherapy. Therefore we continue on our mission at GU Cast to educate ourselves about the use of ARPIs in mHSPC. And yes, e ..read more

SABR supremos Piet Ost and Shankar Siva join us to discuss the management of lymph node-only recurrence following primary treatment of prostate cancer. And of course our resident PSMA PET/CT guru Michael Hofman also turned up as himself and Piet love debating the merits of PSMA! How and when shoudl we image for biochemical recurrence? What are the limits of SABR? WHat about systemic therapy? It's all in this episode with great leaders in the field. Recorded on site at Peter Mac on the fringe of the 2023 SABR Symposium. With your usual hosts Renu Eapen and Declan Murphy Even better on our YouTu ..read more

Prof Fred Saad (University of Montreal) drops in to chat about the interesting condition that is non-metastatic castration-resistant prostate cancer (nmCRPC). Which men are at risk of developing metastases? When should we use an AR pathway inhibitor? Why PSMA PET/CT should NOT be used. And hear his thoughts on "dabbling" in prostate cancer! Also joined by Professor Shankar Siva and Dr Louise Kostos from Peter MacCallum Cancer Centre. Hosted as ever by Dr Renu Eapen and Professor Declan Murphy. Fred was on a speaker tour in Australia supported by Bayer Pharmaceuticals and this Themed Podcast is ..read more

What a great ESMO for GU Oncology!! Declan caught up with some plenary speakers in Madrid to discuss the biggest topics. PSMA theranostics with Louise Emmett (ENZA-P) and Oliver Sartor (PSMAfore); ARPIs in biochemical recurrence with Steve Freedland (EMBARK), Morgan Roupret and Boris Hadaschik. Plus the latest negative immunotherapy trials in prostate cancer with Christian Gratzke. Even better on our YouTube channel  ..read more

The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion. Even better on our YouTube channel Thanks ..read more

We hijacked our good friends Professor Boris Hadaschik (Urologist, Essen, Germany), and Associate Professor Tyler Seibert (Radiation Oncologist, University of California, San Diego), who happened to be in Melbourne this week, and diverted them into the GU Cast studio for a chat about high-risk prostate cancer. Boris and Tyler were on a speaker tour supported Janssen Pharmaceuticals, so we put together this Themed Podcast supported by Janssen (Gold Partners of GU Cast), to probe three key questions in high-risk prostate cancer in 2023: 1. What is the role of PSMA PET/CT in initial staging? 2. I ..read more

The European Association of Nuclear Medicine (EANM) Annual Meeting is the World's leading nuclear medicine extravaganza! Today we cross live to Professor Michael Hofman and friends to hear some of the GU highlights at this year's annual meeting in Vienna.  Michael is joined by Prof Ken Herrmann, Dr Kerry Jewell, Dr Francesco Ceci, Dr Phiilip Kuo, Dr Bastiaan Privé and Dr Wolfgang Fendler. A fantastic update from EANM in Vienna! Even better on our YouTube channel ..read more

The mass media were quick to pick up on two papers in JAMA Surgery last week with headlines such as "Patients have better outcomes with female surgeons", and "Should you pick the sex of your surgeon?". So what's it all about?? We chat with lead author of one of these papers. Dr Chris Wallis, Urologist at the University of Toronto, whose looked at outcomes for more than 1.2 million (!!) patients undergoing a range of surgery types, and showed that patients operated on by female surgeons had less complications and better survival. Another study from Sweden showed similar benefits in patients und ..read more

Is this the solution to screening for prostate cancer?? Don't bother with a PSA test and instead screen using a 10 minute MRI scan??! Re-IMAGINE is a very interesting prospective study published in BMJ Oncology this week which did exactly that with some really interesting findings. We are joined by study authors Professor Caroline Moore and Professor Shonit Punwani to discuss. Even better on our YouTube channel Links: BMJ Oncology paper Coverage in Urology Times  ..read more

What is a rectal spacer and do they help reduce side-effects from prostate radiation??! That's today's topic on GU Cast. Renu caught up with rectal spacer enthusiasts Professor Peter Orio (Dana Farber Cancer Institute) and Associate Professor Shankar Siva (Peter MacCallum Cancer Centre) in downtown Melbourne this week to learn all about this topic. Thanks to our friends at Icon Cancer Centre who supported Peter's educational tour to Australia this week. Also watch full video on YouTube Links: Randomised trial of Barrigel recatl spacer in JAMA Oncology 2023 https://jamanetwork.com/journals/jama ..read more